KAYFANDA

This brand name is authorized in Austria, Estonia, France, Italy, Lithuania, Romania.

Active ingredients

The drug KAYFANDA contains one active pharmaceutical ingredient (API):

1	Odevixibat UNII Q76KP2H4XW - ODEVIXIBAT SESQUIHYDRATE
	Odevixibat is a reversible, potent, selective inhibitor of the ileal bile acid transporter (IBAT). Odevixibat acts locally in the distal ileum to decrease the reuptake of bile acids and increase the clearance of bile acids through the colon, reducing the concentration of bile acids in the serum. The extent of reduction of serum bile acids does not correlate with systemic PK.
	Read more about Odevixibat

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
KAYFANDA Hard capsule	MPI, EU: SmPC	European Medicines Agency (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
A05AX05		A Alimentary tract and metabolism → A05 Bile and liver therapy → A05A Bile therapy → A05AX Other drugs for bile therapy
Discover more medicines within A05AX05

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
EE	Ravimiamet	3090327, 3090338, 3090349, 3090350
FR	Base de données publique des médicaments	60103243, 61087240, 67911925, 69332371
IT	Agenzia del Farmaco	051617013, 051617025, 051617037, 051617049
LT	Valstybinė vaistų kontrolės tarnyba	1101293, 1101294, 1101295, 1101296
RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	W70600001, W70601001, W70602001, W70603001